Cargando…

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries

BACKGROUND: In case of orphan drugs applicability of the standard health technology assessment (HTA) process is limited due to scarcity of good clinical and health economic evidence. Financing these premium priced drugs is more controversial in the Central and Eastern European (CEE) region where the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zelei, Tamás, Molnár, Mária J., Szegedi, Márta, Kaló, Zoltán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893267/ https://www.ncbi.nlm.nih.gov/pubmed/27259284 http://dx.doi.org/10.1186/s13023-016-0455-6

Ejemplares similares

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Medical and economic burden of influenza in the elderly population in central and eastern European countries
por: Kovács, Gábor, et al.
Publicado: (2014)

Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology
por: Inotai, András, et al.
Publicado: (2012)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
por: Kolasa, Katarzyna, et al.
Publicado: (2018)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries
por: Kaló, Zoltán, et al.
Publicado: (2020)

Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
por: Kolasa, Katarzyna, et al.
Publicado: (2016)

Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries—A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses
por: Jakab, Ivett, et al.
Publicado: (2020)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
por: Inotai, András, et al.
Publicado: (2020)

Antimicrobial stewardship in Central Eastern European countries
Publicado: (2021)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Cost-of-illness studies in nine Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2019)

Cancer epidemiology in Central and South Eastern European countries
por: Vrdoljak, Eduard, et al.
Publicado: (2011)

NSCLC molecular testing in Central and Eastern European countries
por: Ryska, Ales, et al.
Publicado: (2018)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Rectal Tumour Staging with Endorectal Ultrasound: Is There Any Difference between Western and Eastern European Countries?
por: Fábián, Anna, et al.
Publicado: (2016)

Organization of control of nosocomial infections in Central Eastern European countries
por: Allerberger, Franz, et al.
Publicado: (2019)

Control of hospital acquired infections in Central Eastern European countries
Publicado: (2019)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review
por: Zelei, Tamás, et al.
Publicado: (2021)

Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey
por: Toplak, Nataša, et al.
Publicado: (2010)

Dietary habits in three Central and Eastern European countries: the HAPIEE study
por: Boylan, Sinéad, et al.
Publicado: (2009)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Determinants of substantial public debt reductions in Central and Eastern European Countries
por: Semik, Sofia, et al.
Publicado: (2021)

Overinvestment in selected Central and Eastern European countries: Production and economic effects
por: Pawłowski, Krzysztof Piotr, et al.
Publicado: (2021)

Use of biomarkers in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE
por: Mandrik, Olena, et al.
Publicado: (2015)

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries
por: Orlewska, Ewa, et al.
Publicado: (2011)

Making Patients Pay: Informal Patient Payments in Central and Eastern European Countries
por: Stepurko, Tetiana, et al.
Publicado: (2015)

Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries
por: Kirichenko, Alina, et al.
Publicado: (2022)

HIV‐positive patients diagnosed with COVID‐19 in Central and Eastern European Countries
por: Skrzat‐Klapaczyńska, Agata, et al.
Publicado: (2022)

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts
por: Inotai, Andras, et al.
Publicado: (2018)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Criteria to define rare diseases and orphan drugs: a systematic review protocol
por: Abozaid, Ghada Mohammed, et al.
Publicado: (2022)

Pharmacy network and access to medicines in selected eastern European countries: comparative analysis
por: Lakić, Dragana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l9b5i6cgrjvuo4npjd9u7m66oa